Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive lung disease, COPD for short, leads to problems such as constant coughing and breathing problems. The main risk factor is years of smoking.

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent® for the treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled with existing therapy. [Regeneron Pharmaceuticals, Inc. ] Press Release